Introduction

Based on encouraging results of our first prostate study, we are currently expanding the same clinical protocol study where we are examining the effects of a combination of an EDTA suppository, called Detoxamin and an antibiotic, tetracycline to reduce or eliminate prostate calcifications and the symptoms associated with this condition.

As clinicians, our research team is optimistic by our experiences and outcomes with combination detoxification therapy. In addition, published clinical studies show chelation therapy can effectively remove heavy metal toxin build up (heavy metal toxicity can cause a variety of serious clinical conditions) and dissolve calcium deposits from the body. Further research demonstrates that nanobacteria lodge onto the prostate and form protective coverings and calcifications (similar to kidney stones). The calcifications increase in number and size over time and cause a variety of symptoms which can lead to debilitating diseases. The treatments set forward in this study, have a high probability to address the purported cause of this prostate condition.

Study goals: This 90 day study will utilize detoxification methods to help reduce signs and symptoms of prostatitis, prostate calcifications, BPH and other health challenges caused by toxic build up and infectious agents called nanobacteria.

Brief Protocol: Participants in this study will be required to take a combination of the EDTA suppository (Detoxamin), tetracycline, vitamin/mineral supplements and a probiotic. There are on-line symptom surveys that are to be filled out to evaluate treatment results. Participants will also be able choose ultrasonography and fecal heavy metal analysis tests before and after treatment.

There are significant discounts on diagnostics and test treatments for those men who qualify and are placed in the study.

Enrollment: If you are interested in entering into this research program, please click here to read an Informed Consent that will describe the study in detail.